Study of Correlation Between Serum BDNF Levels and Pfirmann Grading and IL- 1β

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-80
SponsorKeimyung University Dongsan Medical Center

About this trial

Brain-derived neurotrophic factor (BDNF) is a protein belonging to the neurotrophin family, known to be involved in neuronal survival, growth, and synaptic plasticity. Recent studies suggest that the role of BDNF may extend beyond the central nervous system to include inflammatory responses and degenerative changes in peripheral tissues. In particular, BDNF expression has been confirmed within intervertebral disc tissue, with degenerated discs showing increased BDNF expression compared to normal discs, and this expression has been reported to increase further with the severity of degeneration Intervertebral disc degeneration is closely associated with intradiscal nerve ingrowth (neoinnervation) and the resulting generation of pain, and BDNF has been reported as a factor mediating this nerve ingrowth and pain sensitization (central/peripheral sensitization) within the disc. Interleukin-1 beta (IL-1β), a representative inflammatory cytokine of disc degeneration, is known as a key mediator that promotes extracellular matrix degradation within disc tissue and induces neoinnervation and sensitization. Because BDNF secretion from neurons and immune cells has also been reported to increase in inflammatory environments, a potential interaction between IL-1β and BDNF has been proposed Accordingly, this study aims to measure serum BDNF concentrations in patients presenting with low back and leg pain due to disc degeneration or spinal stenosis, and to analyze whether these levels show a consistent correlation with Pfirrmann grading on MRI and serum IL-1β concentration.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

lumbar disc herniation

lumbar spinal canal stenosis

patients who have MRI

Disqualifiers

spine fracture

spine infection

spine tumor

rhematoid arthritis

Trial population

low back pain population with disc degeneration confirmed in MRI

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • blood sampling for ELISA

    Procedure/Surgery

    blood sampling to detect the level of BDNF

Treatment groups

59 Participants
are divided into 1 treatment group
Group A: back pain patient group1 intervention

Trial outcomes

Primary outcomes

1

Idenfifying the correlation of BDNF level and Pfirmann grading

Time frame
day 1

Secondary outcomes

1

Idnetifying the correlation of BDNF level and IL-1β

Time frame
day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.